Linlithgow, United Kingdom

Calum B MacFarlane

This inventor holds 3 USPTO granted patents. Top assignee: Syntex (u.s.a.) Inc.. Active years: 1990-1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Calum B MacFarlane. Retrieved from https://idiyas.com/inventor/calum-b-macfarlane

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 136(Granted Patents)


Company Filing History:


Years Active: 1990-1993

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Calum B MacFarlane: Innovator in Pharmaceutical Compositions

Introduction

Calum B MacFarlane is a notable inventor based in Linlithgow, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of long-acting formulations for calcium channel blockers. With a total of 3 patents to his name, MacFarlane's work is recognized for its innovative approach to drug delivery.

Latest Patents

One of his latest patents is for a long-acting calcium channel blocker composition. This invention discloses an improved long-acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers. The composition features calcium channel blockers and a pH-dependent binder, which are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter. The formulation is designed with a coating that allows for slow, sustained release of a therapeutically effective amount of the calcium channel blocker over a period of at least about 24 hours. This advancement makes the pharmaceutical composition suitable for once-daily administration.

Another significant patent by MacFarlane is a long-acting nicardipine hydrochloride formulation. Similar to his previous work, this sustained release pharmaceutical composition also involves dihydropyridine calcium channel blockers. The formulation is characterized by the same intimate admixture of calcium channel blockers and pH-dependent binders in spherically shaped particles, ensuring effective drug delivery.

Career Highlights

Calum B MacFarlane has established himself as a key figure in pharmaceutical innovation. He is currently associated with Syntex (U.S.A.) Inc., where he continues to develop groundbreaking formulations that enhance patient care. His work is instrumental in advancing the efficacy and safety of calcium channel blocker medications.

Collaborations

MacFarlane has collaborated with notable colleagues, including Alastair B Selkirk and Michael J Dey. These partnerships have contributed to the successful development of his patented formulations and have fostered a collaborative environment for innovation.

Conclusion

Calum B MacFarlane's contributions to pharmaceutical sciences, particularly in the area of long-acting calcium channel blockers, highlight his role as an influential inventor. His patents reflect a commitment to improving drug delivery systems, ultimately benefiting patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…